Development of a novel RNA-based microsatellite stable predictive response signature (MSS-PRS) to identify MSS colorectal cancer (CRC) patients with a microsatellite instability-high (MSI-H) molecular phenotype

被引：0
|
作者：
Pappan, Kirk
Mayhew, Gregory
Shepherd, Jonathan
Guo, Yuelong
Beebe, Kirk
Eisner, Joel
Milburn, Michael
机构：
来源：
CANCER RESEARCH | 2024年 / 84卷 / 06期
关键词：
D O I：
10.1158/1538-7445.AM2024-1040
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1040
引用
收藏
页数：2
相关论文
共 43 条
  • [41] Colorectal cancer metastatic dMMR immunotherapy (COMMIT) study: A randomized phase III study of atezolizumab (atezo) monotherapy versus mFOLFOX6/bevacizumab/atezo in the first-line treatment of patients with deficient DNA mismatch repair (dMMR) or microsatellite instability-high (MSI-H) metastatic colorectal cancer 9NRG-GI004/SWOG-S1610).
    Overman, Michael J.
    Yothers, Greg
    Puhalla, Shannon L.
    Sanoff, Hanna Kelly
    Cohen, Deirdre J.
    Guthrie, Katherine A.
    Ganz, Patricia A.
    Kopetz, Scott
    Lucas, Peter C.
    Blanke, Charles D.
    Jacobs, Samuel A.
    Hong, Theodore S.
    Wolmark, Norman
    Hochster, Howard S.
    George, Thomas J.
    Lima, Caio Max Sao Pedro Rocha
    JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (4_SUPPL) : TPS311 - TPS311
  • [42] NRG-GI004/SWOG-S1610: Colorectal cancer metastatic dMMR immuno-therapy (COMMIT) study-A randomized phase III study of atezolizumab (atezo) monotherapyversus mFOLFOX6/bevacizumab/atezo in the first-line treatment of patients with deficient DNA mismatch repair (dMMR) or microsatellite instability-high (MSI-H) metastatic colorectal cancer (mCRC).
    Lima, Caio Max Sao Pedro Rocha
    Yothers, Greg
    Puhalla, Shannon L.
    Sanoff, Hanna Kelly
    Cohen, Deirdre J.
    Guthrie, Katherine A.
    Henry, Norah Lynn
    Ganz, Patricia A.
    Kopetz, Scott
    Lucas, Peter C.
    Blanke, Charles D.
    Jacobs, Samuel A.
    Hong, Theodore S.
    Wolmark, Norman
    Hochster, Howard S.
    George, Thomas J.
    Overman, Michael J.
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [43] Colorectal cancer metastatic dMMR immuno-therapy (COMMIT) study: A randomized phase III study of atezolizumab (atezo) monotherapy versus mFOLFOX6/bevacizumab/atezo in the first-line treatment of patients (pts) with deficient DNA mismatch repair (dMMR) or microsatellite instability-high (MSI-H) metastatic colorectal cancer (mCRC)-NRG-GI004/SWOG-S1610
    Overman, Michael J.
    Yothers, Greg
    Jacobs, Samuel A.
    Sanoff, Hanna Kelly
    Cohen, Deirdre J.
    Guthrie, Katherine A.
    Henry, Norah Lynn
    Ganz, Patricia A.
    Kopetz, Scott
    Lucas, Peter C.
    Blanke, Charles D.
    Hong, Theodore S.
    Wolmark, Norman
    Hochster, Howard S.
    George, Thomas J.
    Lima, Caio Max Sao Pedro Rocha
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (3_SUPPL) : TPS231 - TPS231
12345